Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Review Article

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies

Abstract

In 1990, more than 10 years after the discovery that the low molecular weight GTPase Ras is a major contributor to human cancer, farnesylation, a lipid posttranslational modification required for the cancer-causing activity of Ras, emerged as a major target for the development of novel anticancer agents. However, it took only 5 years from 1993, when the first farnesyltransferase inhibitors (FTIs) were reported, to 1998 when results from the first phase I clinical trials were described. This rapid progress was due to the demonstration of outstanding antitumor activity and lack of toxicity of FTIs in preclinical models. Although, many FTIs are currently in phase II and at least one is in phase III clinical trial, the mechanism of FTI antitumor activity is not known. In this review a brief summary of the development of FTIs as antitumor agents will be given. The focus of the review will be on important mechanistic and bench-to-bedside translational issues. Among the issues that will be addressed are: evidence for and against inhibition of the prenylation of Ras and RhoB proteins in the mechanism of action of FTIs; implications of the alternative prenylation of K-Ras by geranylgeranyltransferase I (when FTase is inhibited) in cancer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycle machinery and progression and potential mechanisms by which FTIs and GGTIs induce apoptosis in human cancer cells. A thorough discussion about bench-to-bedside issues relating to hypothesis-driven clinical trials with proof-of-principle in man will also be included. This section will cover issues relating to whether the biochemical target (FTase) is inhibited and the level of inhibition of FTase required for clinical response; are signaling pathways such as H-Ras/PI3K/Akt and/or K-Ras/Raf/MEK/Erk relevant biological readouts?; is Ras (particularly N-Ras and H-Ras) mutation status a good predictor of clinical response?; in phase I trials should effective biological dose, not maximally tolerated dose, be used to determine phase II dose?; and finally, in phase II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as FTIs? Parts of this topic have been recently reviewed (Sebti and Hamilton, 2000c).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  • Adamson P, Marshall CJ, Hall A and Tilbrook PA. . 1992 J. Biol. Chem. 267: 20033–20038.

  • Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P and Kaufmann SH. . 2000 Cancer Res. 60: 1871–1877.

  • Adnane J, Bizouarn FA, Qian Y, Hamilton AD and Sebti SM. . 1998 Mol. Cell. Biol. 18: 6962–6970.

  • Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR and Kirschmeier P. . 2000 J. Biol. Chem. 275: 30451–30457.

  • Barbacid M. . 1986 Important Adv. Oncol. 3–22.

  • Barbacid M. . 1987 Annu. Rev. Biochem. 56: 779–827.

  • Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ and McKenna WG. . 1996 Cancer Res. 56: 1727–1730.

  • Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM and Muschel RJ. . 1998 Cancer Res. 58: 1754–1761.

  • Bredel M, Pollack IF, Freund JM, Hamilton AD and Sebti SM. . 1998 Neurosurgery 43: 124–131; discussion 131–132.

  • Britten CD, Rowinsky E, Yao S-L, Soignet S, Rosen N, Eckhardt SG, Drengler R, Hammond L, Siv LL, Smith L, McCreery H, Pezzulli S, Lee Y, Lobell R, Deutsch P, Von Hoff P and Spriggs D. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 155a.

  • Casey PJ. . 1992 J. Lipid. Res. 33: 1731–1740.

  • Chen Z, Sun J, Pradines A, Favre G, Adnane J and Sebti SM. . 2000 J. Biol. Chem. 275: 17974–17978.

  • Cox AD and Der CJ. . 1997 Biochim. Biophys Acta 1333: F51–F71.

  • Crespo N, Ohkanda J, Yen T, Hamilton AD and Sebti SM. . 2001 J. Biol. Chem. In press.

  • Du W, Liu A and Prendergast GC. . 1999 Cancer Res. 59: 4208–4212.

  • Du W and Prendergast GC. . 1999 Cancer Res. 59: 5492–5496.

  • Eskens F, Awada A, Verweij J, Cutler DL, Hanauske A and Piccart M. . 1999 Proc. Am. Soc. Oncol. 18: 156a.

  • Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Omer C, Pellicier A, Windle J and Oliff A. . 2000 Farnesyltransferase Inhibitors in Cancer Therapy. Hamilton SMSaAD. (ed.). Humana Press Inc.: Totowa, NJ pp. 65–70.

  • Gibbs JB and Oliff A. . 1997 Annu. Rev. Pharmacol. Toxicol. 37: 143–166.

  • Hahn SM, Kiel K, Morrison BW, Mohiuddin MM, Thomas D, Smith D, Brown R, Brown R, Pramanik B, Kher U, Deutsch P and McKenna WG. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 231a.

  • Hudes GR, Schol J, Baab J, Rogatko A, Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ and Weiner L. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 156a.

  • Hurwitz HI, Amado R, Prager D, Hecht JR, Cohen DP, Conway D, Kadib L, Mayers A, Calzetta A, Statkevich P, Cutler DL and Rosen LS. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 185a.

  • James GL, Goldstein JL and Brown MS. . 1995 J. Biol. Chem. 270: 6221–6226.

  • Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM and Cheng JQ. . 2000 Mol. Cell. Biol. 20: 139–148.

  • Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD and Carthew RW. . 1995 Proc. Natl. Acad. Sci. USA 92: 10919–10923.

  • Khosravi-Far R, Solski PA, Clark GJ, Kinch MS and Der CJ. . 1995 Mol. Cell. Biol. 15: 6443–6453.

  • Khuri FR, Glisson BS, Meyers ML, Herbst RS, Thall PF, Munden RF, Bangert S, Cascino M, Blumenschein G, Pisters K and Hong WK. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 205a.

  • Lancet JE, Rosenblatt JD, Liesveld JL, End D, Horak I, Ange D, Rosell KE, Petronio S, Smith AJ and Karp JE. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 3a.

  • Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA and You M. . 2000 Carcinogenesis 21: 113–116.

  • Lebowitz PF, Casey PJ, Prendergast GC and Thissen JA. . 1997a J. Biol. Chem. 272: 15591–15594.

  • Lebowitz PF, Davide JP and Prendergast GC. . 1995 Mol. Cell. Biol. 15: 6613–6622.

  • Lebowitz PF, Sakamuro D and Prendergast GC. . 1997b Cancer Res. 57: 708–713.

  • Lee J, Miyano T, Dai Y, Wooding P, Yen TJ and Moor RM. . 2000 Mol. Reprod. Dev. 56: 51–62.

  • Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD and Sebti SM. . 1995a J. Biol. Chem. 270: 26802–26806.

  • Lerner EC, Qian Y, Hamilton AD and Sebti SM. . 1995b J. Biol. Chem. 270: 26770–26773.

  • Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD and Sebti SM. . 1997 Oncogene 15: 1283–1288.

  • Liu A, Du W, Liu JP, Jessell TM and Prendergast GC. . 2000 Mol. Cell. Biol. 20: 6105–6113.

  • McGuire TF, Qian Y, Vogt A, Hamilton AD and Sebti SM. . 1996 J. Biol. Chem. 271: 27402–27407.

  • Nagasu T, Yoshimatsu K, Rowell C, Lewis MD and Garcia AM. . 1995 Cancer Res. 55: 5310–5314.

  • Nigam M, Seong CM, Qian Y, Hamilton AD and Sebti SM. . 1993 J. Biol. Chem. 268: 20695–20698.

  • Olson MF, Paterson HF and Marshall CJ. . 1998 Nature 394: 295–299.

  • Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A and Kohl NE. . 2000 Cancer Res. 60: 2680–2688.

  • Patnaik A and Rowinsky EK. . 2000 Farnesyltransferase Inhibitors in Cancer Therapy. Hamilton SMSaAD. (ed.). Humana Press, Inc: Totowa, NJ pp. 233–249.

  • Pollack IF, Bredel M, Erff M, Hamilton AD and Sebti SM. . 1999 Neurosurgery 45: 1208–1214; discussion 1214–1215.

  • Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A and Kohl NE. . 1994 Mol. Cell. Biol. 14: 4193–4202.

  • Qian Y, Blaskovich MA, Seong C-M, Vogt A, Hamilton AD, Sebti SM. . 1994 Biog. Med. Chem. Lett. 4: 2579–2584.

  • Qiu RG, Chen J, McCormick F and Symons M. . 1995 Proc. Natl. Acad. Sci. USA 92: 11781–11785.

  • Reiss Y, Goldstein JL, Seabra MC, Casey PJ and Brown MS. . 1990 Cell 62: 81–88.

  • Robinet G, Thomas P, Perol M, Vergnenegre A, Lena H, Taytard A, Paillotin D, Bessa EH and Schuller-Lebeau MP. . 2000 Bull. Cancer 87: 253–258.

  • Rowell CA, Kowalczyk JJ, Lewis MD and Garcia AM. . 1997 J. Biol. Chem. 272: 14093–14097.

  • Ryan DP, Eder JP, Supko JG, Lunch TJ, Amrein PC, Fuchs CS, Roper K, Washington T, Sonnichsen D, Tuck D and Clark JW. . 2000 ASCO Annual Meeting: New Orleans, LA.

    Google Scholar 

  • Sebti SM and Hamilton AD. . 1997a Exp. Opin. Invest. Drugs 6: 1711–1714.

  • Sebti SM and Hamilton AD. . 1997b Pharmacol. Ther. 74: 103–114.

  • Sebti SM and Hamilton AD. . 2000a Farnesyltransferase Inhibitors in Cancer Therapy. Sebti SM and Hamilton AD (eds). Humana Press Inc.: Totowa, NJ pp. 197–219.

  • Sebti SM and Hamilton AD. . 2000b Farnesyltransferase Inhibitors in Cancer Therapy. Sebti SM and Hamilton AD (eds). Human Press, Inc., Totowa, NJ pp. 1–280.

  • Sebti SM and Hamilton AD. . 2000c Exp. Opin. Invest. Drugs 9: pp. 2767–2782.

  • Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A and Rosen N. . 1995 Cancer Res. 55: 5302–5309.

  • Sepp-Lorenzino L and Rosen N. . 1998 J. Biol. Chem. 273: 20243–20251.

  • Shih TY, Stokes PE, Smythers GW, Dhar R and Oroszlan S. . 1982 J. Biol. Chem. 257: 11767–11773.

  • Soignet S, Yao S-L, Britten C, Spriggs D, Pezzulli S, McCreery H, Mazina K, Deutsch P, Lee Y, Lobell R, Rosen N and Rowinsky E. . 1999 Proc. Am. Assoc. Can. Res. 40: 517.

  • Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD and Sebti SM. . 1999a Cancer Res. 59: 4919–4926.

  • Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD and Sebti SM. . 1999b J. Biol. Chem. 274: 6930–6934.

  • Sun J, Qian Y, Hamilton AD and Sebti SM. . 1995 Cancer Res. 55: 4243–4247.

  • Sun J, Qian Y, Hamilton AD and Sebti SM. . 1998 Oncogene 16: 1467–1473.

  • Suzuki N, Urano J and Tamanoi F. . 1998 Proc. Natl. Acad. Sci. USA 95: 15356–15361.

  • Vogt A, Qian Y, McGuire TF, Hamilton AD and Sebti SM. . 1996 Oncogene 13: 1991–1999.

  • Vogt A, Sun J, Qian Y, Hamilton AD and Sebti SM. . 1997 J. Biol. Chem. 272: 27224–27229.

  • Voice JK, Klemke RL, Le A and Jackson JH. . 1999 J. Biol. Chem. 274: 17164–17170.

  • Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR and Pai JK. . 1997 J. Biol. Chem. 272: 14459–14464.

  • Yan J, Roy S, Apolloni A, Lane A and Hancock JF. . 1998 J. Biol. Chem. 273: 24052–24056.

  • Zalcman G, Closson V, Linares-Cruz G, Lerebours F, Honore N, Tavitian A and Olofsson B. . 1995 Oncogene 10: 1935–1945.

  • Zhang FL and Casey PJ. . 1996 Annu. Rev. Biochem. 65: 241–269.

  • Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL and Der CJ. . 1998 Oncogene 17: 1415–1438.

  • Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB and Cowan KH. . 2000 J. Clin. Oncol. 18: 927–941.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sebti, S., Hamilton, A. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593 (2000). https://doi.org/10.1038/sj.onc.1204146

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204146

Keywords

This article is cited by

Search

Quick links